To date, among the requests for medical help with headaches, a significant part of patients are people with paroxysmal headaches accompanied by pronounced autonomic disorders. This group of headaches belongs to terminal vegetative cephalgia and requires a new approach in therapy with the use of modern medications. The drug irinex (erenumab), used as a solution for subcutaneous administration, proved to be one of the most effective antimegrenous agents. Within the framework of this scientific work, the results of the use of the drug irinex in the treatment of cluster headaches and other trigeminal autonomic cephalgias were considered. The study used an indicator of the average monthly frequency of headaches in patients, as well as a subjective scale of severity of autonomic disorders. The drug Iirinex is a modern anti-migraine drug, used as a solution for subcutaneous administration and contains the active substance - erenumab. As a result of the study, there was a general decrease in the frequency of painful paroxysms for 6 months with regular use of the drug at a dosage of 140 mg and an increase in the level of physical activity of patients. Thus, the use of the drug irinex has shown high efficacy and safety in the treatment of cluster headaches and other trigeminal autonomic cephalgias.